The global Leuprorelin Drugs market was valued at US$ 2580 million in 2023 and is anticipated to reach US$ 3811 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.

Leuprorelin Drugs Market

Leuprorelin drugs are a class of medications that feature leuprorelin, a synthetic analog of gonadotropin-releasing hormone (GnRH). These drugs are designed to modulate hormone levels by initially stimulating and then suppressing the pituitary gland's release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression effectively lowers the production of sex hormones such as testosterone and estrogen. Leuprorelin is used to treat various conditions, including prostate cancer, endometriosis, and uterine fibroids.

Initially introduced as a treatment for hormone-dependent cancers and other conditions, early formulations of leuprorelin were primarily injectable solutions requiring frequent administration. This approach was effective but posed challenges in terms of patient compliance and convenience, as regular injections were needed to maintain therapeutic levels of the medication.

In response to these challenges, the development trend shifted towards extended-release formulations. Innovations in drug delivery systems led to the creation of leuprorelin implants and depot injections, which allow for sustained, long-term release of the drug. These formulations reduce the frequency of administration from monthly to quarterly or even semi-annually, improving patient convenience and adherence to treatment regimens. Such advancements have expanded the use of leuprorelin in managing chronic conditions by providing more stable hormonal control and minimizing the burden of frequent medical visits.

Looking ahead, ongoing research in the field aims to further enhance the efficacy and safety profile of leuprorelin drugs. Efforts are focused on developing novel delivery systems, such as biodegradable implants and advanced depot formulations, which could offer even more extended release and reduced side effects. Additionally, there is a growing interest in exploring new therapeutic indications and combination therapies that could leverage leuprorelin's hormonal modulation properties for broader applications. This forward momentum underscores a commitment to refining leuprorelin treatments to better meet patient needs and improve overall therapeutic outcomes.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Leuprorelin Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leuprorelin Drugs.

The Leuprorelin Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Leuprorelin Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Leuprorelin Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Leuprorelin Drugs Market Report

Report Metric	Details
Report Name	Leuprorelin Drugs Market
Accounted market size in 2023	US$ 2580 million
Forecasted market size in 2030	US$ 3811 million
CAGR	5.6%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Tablets Injections Implants
Segment by Application	Central Precocious Puberty Advanced Prostate Cancer Uterine Fibroids Endometriosis Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Takeda Pharmaceutical, AbbVie, Merck, Sun Pharmaceutical, Eugia Pharma, Cipla, Tolmar, Accord BioPharma, Foresee Pharmaceuticals, Beijing Biote Pharmaceutical, Livzon Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Leuprorelin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Leuprorelin Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Leuprorelin Drugs Market growing?

Ans: The Leuprorelin Drugs Market witnessing a CAGR of 5.6% during the forecast period 2024-2030.

What is the Leuprorelin Drugs Market size in 2030?

Ans: The Leuprorelin Drugs Market size in 2030 will be US$ 3811 million.

Who are the main players in the Leuprorelin Drugs Market report?

Ans: The main players in the Leuprorelin Drugs Market are Takeda Pharmaceutical, AbbVie, Merck, Sun Pharmaceutical, Eugia Pharma, Cipla, Tolmar, Accord BioPharma, Foresee Pharmaceuticals, Beijing Biote Pharmaceutical, Livzon Pharmaceutical

What are the Application segmentation covered in the Leuprorelin Drugs Market report?

Ans: The Applications covered in the Leuprorelin Drugs Market report are Central Precocious Puberty, Advanced Prostate Cancer, Uterine Fibroids, Endometriosis, Other

What are the Type segmentation covered in the Leuprorelin Drugs Market report?

Ans: The Types covered in the Leuprorelin Drugs Market report are Tablets, Injections, Implants

1 Leuprorelin Drugs Market Overview

1.1 Product Definition

1.2 Leuprorelin Drugs by Type

1.2.1 Global Leuprorelin Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Tablets

1.2.3 Injections

1.2.4 Implants

1.3 Leuprorelin Drugs by Application

1.3.1 Global Leuprorelin Drugs Market Value by Application (2024-2030)

1.3.2 Central Precocious Puberty

1.3.3 Advanced Prostate Cancer

1.3.4 Uterine Fibroids

1.3.5 Endometriosis

1.3.6 Other

1.4 Global Leuprorelin Drugs Market Size Estimates and Forecasts

1.4.1 Global Leuprorelin Drugs Revenue 2019-2030

1.4.2 Global Leuprorelin Drugs Sales 2019-2030

1.4.3 Global Leuprorelin Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Leuprorelin Drugs Market Competition by Manufacturers

2.1 Global Leuprorelin Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Leuprorelin Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Leuprorelin Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Leuprorelin Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Leuprorelin Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Leuprorelin Drugs, Product Type & Application

2.7 Global Key Manufacturers of Leuprorelin Drugs, Date of Enter into This Industry

2.8 Global Leuprorelin Drugs Market Competitive Situation and Trends

2.8.1 Global Leuprorelin Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Leuprorelin Drugs Players Market Share by Revenue

2.8.3 Global Leuprorelin Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Leuprorelin Drugs Market Scenario by Region

3.1 Global Leuprorelin Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Leuprorelin Drugs Sales by Region: 2019-2030

3.2.1 Global Leuprorelin Drugs Sales by Region: 2019-2024

3.2.2 Global Leuprorelin Drugs Sales by Region: 2025-2030

3.3 Global Leuprorelin Drugs Revenue by Region: 2019-2030

3.3.1 Global Leuprorelin Drugs Revenue by Region: 2019-2024

3.3.2 Global Leuprorelin Drugs Revenue by Region: 2025-2030

3.4 North America Leuprorelin Drugs Market Facts & Figures by Country

3.4.1 North America Leuprorelin Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Leuprorelin Drugs Sales by Country (2019-2030)

3.4.3 North America Leuprorelin Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Leuprorelin Drugs Market Facts & Figures by Country

3.5.1 Europe Leuprorelin Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Leuprorelin Drugs Sales by Country (2019-2030)

3.5.3 Europe Leuprorelin Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Leuprorelin Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Leuprorelin Drugs Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Leuprorelin Drugs Sales by Region (2019-2030)

3.6.3 Asia Pacific Leuprorelin Drugs Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Leuprorelin Drugs Market Facts & Figures by Country

3.7.1 Latin America Leuprorelin Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Leuprorelin Drugs Sales by Country (2019-2030)

3.7.3 Latin America Leuprorelin Drugs Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Leuprorelin Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Leuprorelin Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Leuprorelin Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Leuprorelin Drugs Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Leuprorelin Drugs Sales by Type (2019-2030)

4.1.1 Global Leuprorelin Drugs Sales by Type (2019-2024)

4.1.2 Global Leuprorelin Drugs Sales by Type (2025-2030)

4.1.3 Global Leuprorelin Drugs Sales Market Share by Type (2019-2030)

4.2 Global Leuprorelin Drugs Revenue by Type (2019-2030)

4.2.1 Global Leuprorelin Drugs Revenue by Type (2019-2024)

4.2.2 Global Leuprorelin Drugs Revenue by Type (2025-2030)

4.2.3 Global Leuprorelin Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Leuprorelin Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Leuprorelin Drugs Sales by Application (2019-2030)

5.1.1 Global Leuprorelin Drugs Sales by Application (2019-2024)

5.1.2 Global Leuprorelin Drugs Sales by Application (2025-2030)

5.1.3 Global Leuprorelin Drugs Sales Market Share by Application (2019-2030)

5.2 Global Leuprorelin Drugs Revenue by Application (2019-2030)

5.2.1 Global Leuprorelin Drugs Revenue by Application (2019-2024)

5.2.2 Global Leuprorelin Drugs Revenue by Application (2025-2030)

5.2.3 Global Leuprorelin Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Leuprorelin Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Takeda Pharmaceutical

6.1.1 Takeda Pharmaceutical Company Information

6.1.2 Takeda Pharmaceutical Description and Business Overview

6.1.3 Takeda Pharmaceutical Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Takeda Pharmaceutical Leuprorelin Drugs Product Portfolio

6.1.5 Takeda Pharmaceutical Recent Developments/Updates

6.2 AbbVie

6.2.1 AbbVie Company Information

6.2.2 AbbVie Description and Business Overview

6.2.3 AbbVie Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AbbVie Leuprorelin Drugs Product Portfolio

6.2.5 AbbVie Recent Developments/Updates

6.3 Merck

6.3.1 Merck Company Information

6.3.2 Merck Description and Business Overview

6.3.3 Merck Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Merck Leuprorelin Drugs Product Portfolio

6.3.5 Merck Recent Developments/Updates

6.4 Sun Pharmaceutical

6.4.1 Sun Pharmaceutical Company Information

6.4.2 Sun Pharmaceutical Description and Business Overview

6.4.3 Sun Pharmaceutical Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Sun Pharmaceutical Leuprorelin Drugs Product Portfolio

6.4.5 Sun Pharmaceutical Recent Developments/Updates

6.5 Eugia Pharma

6.5.1 Eugia Pharma Company Information

6.5.2 Eugia Pharma Description and Business Overview

6.5.3 Eugia Pharma Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Eugia Pharma Leuprorelin Drugs Product Portfolio

6.5.5 Eugia Pharma Recent Developments/Updates

6.6 Cipla

6.6.1 Cipla Company Information

6.6.2 Cipla Description and Business Overview

6.6.3 Cipla Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Cipla Leuprorelin Drugs Product Portfolio

6.6.5 Cipla Recent Developments/Updates

6.7 Tolmar

6.7.1 Tolmar Company Information

6.7.2 Tolmar Description and Business Overview

6.7.3 Tolmar Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Tolmar Leuprorelin Drugs Product Portfolio

6.7.5 Tolmar Recent Developments/Updates

6.8 Accord BioPharma

6.8.1 Accord BioPharma Company Information

6.8.2 Accord BioPharma Description and Business Overview

6.8.3 Accord BioPharma Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Accord BioPharma Leuprorelin Drugs Product Portfolio

6.8.5 Accord BioPharma Recent Developments/Updates

6.9 Foresee Pharmaceuticals

6.9.1 Foresee Pharmaceuticals Company Information

6.9.2 Foresee Pharmaceuticals Description and Business Overview

6.9.3 Foresee Pharmaceuticals Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Foresee Pharmaceuticals Leuprorelin Drugs Product Portfolio

6.9.5 Foresee Pharmaceuticals Recent Developments/Updates

6.10 Beijing Biote Pharmaceutical

6.10.1 Beijing Biote Pharmaceutical Company Information

6.10.2 Beijing Biote Pharmaceutical Description and Business Overview

6.10.3 Beijing Biote Pharmaceutical Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Beijing Biote Pharmaceutical Leuprorelin Drugs Product Portfolio

6.10.5 Beijing Biote Pharmaceutical Recent Developments/Updates

6.11 Livzon Pharmaceutical

6.11.1 Livzon Pharmaceutical Company Information

6.11.2 Livzon Pharmaceutical Description and Business Overview

6.11.3 Livzon Pharmaceutical Leuprorelin Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Livzon Pharmaceutical Leuprorelin Drugs Product Portfolio

6.11.5 Livzon Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Leuprorelin Drugs Industry Chain Analysis

7.2 Leuprorelin Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Leuprorelin Drugs Production Mode & Process

7.4 Leuprorelin Drugs Sales and Marketing

7.4.1 Leuprorelin Drugs Sales Channels

7.4.2 Leuprorelin Drugs Distributors

7.5 Leuprorelin Drugs Customers

8 Leuprorelin Drugs Market Dynamics

8.1 Leuprorelin Drugs Industry Trends

8.2 Leuprorelin Drugs Market Drivers

8.3 Leuprorelin Drugs Market Challenges

8.4 Leuprorelin Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical

Foresee Pharmaceuticals

Beijing Biote Pharmaceutical

Livzon Pharmaceutical

Accord BioPharma

List of Tables

Table 1. Global Leuprorelin Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Leuprorelin Drugs Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Leuprorelin Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Leuprorelin Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Leuprorelin Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Leuprorelin Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Leuprorelin Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Leuprorelin Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Leuprorelin Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Leuprorelin Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Leuprorelin Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Leuprorelin Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Leuprorelin Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leuprorelin Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Leuprorelin Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Leuprorelin Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global Leuprorelin Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Leuprorelin Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global Leuprorelin Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Leuprorelin Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Leuprorelin Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Leuprorelin Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Leuprorelin Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Leuprorelin Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Leuprorelin Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America Leuprorelin Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America Leuprorelin Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Leuprorelin Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Leuprorelin Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Leuprorelin Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe Leuprorelin Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe Leuprorelin Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Leuprorelin Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Leuprorelin Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Leuprorelin Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Leuprorelin Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Leuprorelin Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Leuprorelin Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Leuprorelin Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Leuprorelin Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Leuprorelin Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Leuprorelin Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Leuprorelin Drugs Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Leuprorelin Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Leuprorelin Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Leuprorelin Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Leuprorelin Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Leuprorelin Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Leuprorelin Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global Leuprorelin Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global Leuprorelin Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Leuprorelin Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Leuprorelin Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Leuprorelin Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Leuprorelin Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Leuprorelin Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Leuprorelin Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Leuprorelin Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Leuprorelin Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global Leuprorelin Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global Leuprorelin Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Leuprorelin Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Leuprorelin Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Leuprorelin Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Leuprorelin Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Leuprorelin Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Leuprorelin Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Leuprorelin Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Takeda Pharmaceutical Company Information

Table 71. Takeda Pharmaceutical Description and Business Overview

Table 72. Takeda Pharmaceutical Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Takeda Pharmaceutical Leuprorelin Drugs Product

Table 74. Takeda Pharmaceutical Recent Developments/Updates

Table 75. AbbVie Company Information

Table 76. AbbVie Description and Business Overview

Table 77. AbbVie Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. AbbVie Leuprorelin Drugs Product

Table 79. AbbVie Recent Developments/Updates

Table 80. Merck Company Information

Table 81. Merck Description and Business Overview

Table 82. Merck Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Merck Leuprorelin Drugs Product

Table 84. Merck Recent Developments/Updates

Table 85. Sun Pharmaceutical Company Information

Table 86. Sun Pharmaceutical Description and Business Overview

Table 87. Sun Pharmaceutical Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Sun Pharmaceutical Leuprorelin Drugs Product

Table 89. Sun Pharmaceutical Recent Developments/Updates

Table 90. Eugia Pharma Company Information

Table 91. Eugia Pharma Description and Business Overview

Table 92. Eugia Pharma Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Eugia Pharma Leuprorelin Drugs Product

Table 94. Eugia Pharma Recent Developments/Updates

Table 95. Cipla Company Information

Table 96. Cipla Description and Business Overview

Table 97. Cipla Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Cipla Leuprorelin Drugs Product

Table 99. Cipla Recent Developments/Updates

Table 100. Tolmar Company Information

Table 101. Tolmar Description and Business Overview

Table 102. Tolmar Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Tolmar Leuprorelin Drugs Product

Table 104. Tolmar Recent Developments/Updates

Table 105. Accord BioPharma Company Information

Table 106. Accord BioPharma Description and Business Overview

Table 107. Accord BioPharma Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Accord BioPharma Leuprorelin Drugs Product

Table 109. Accord BioPharma Recent Developments/Updates

Table 110. Foresee Pharmaceuticals Company Information

Table 111. Foresee Pharmaceuticals Description and Business Overview

Table 112. Foresee Pharmaceuticals Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Foresee Pharmaceuticals Leuprorelin Drugs Product

Table 114. Foresee Pharmaceuticals Recent Developments/Updates

Table 115. Beijing Biote Pharmaceutical Company Information

Table 116. Beijing Biote Pharmaceutical Description and Business Overview

Table 117. Beijing Biote Pharmaceutical Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Beijing Biote Pharmaceutical Leuprorelin Drugs Product

Table 119. Beijing Biote Pharmaceutical Recent Developments/Updates

Table 120. Livzon Pharmaceutical Company Information

Table 121. Livzon Pharmaceutical Description and Business Overview

Table 122. Livzon Pharmaceutical Leuprorelin Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Livzon Pharmaceutical Leuprorelin Drugs Product

Table 124. Livzon Pharmaceutical Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Leuprorelin Drugs Distributors List

Table 128. Leuprorelin Drugs Customers List

Table 129. Leuprorelin Drugs Market Trends

Table 130. Leuprorelin Drugs Market Drivers

Table 131. Leuprorelin Drugs Market Challenges

Table 132. Leuprorelin Drugs Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Leuprorelin Drugs

Figure 2. Global Leuprorelin Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Leuprorelin Drugs Market Share by Type: 2023 & 2030

Figure 4. Tablets Product Picture

Figure 5. Injections Product Picture

Figure 6. Implants Product Picture

Figure 7. Global Leuprorelin Drugs Market Value by Application (2024-2030) & (US$ Million)

Figure 8. Global Leuprorelin Drugs Market Share by Application: 2023 & 2030

Figure 9. Central Precocious Puberty

Figure 10. Advanced Prostate Cancer

Figure 11. Uterine Fibroids

Figure 12. Endometriosis

Figure 13. Other

Figure 14. Global Leuprorelin Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Leuprorelin Drugs Market Size (2019-2030) & (US$ Million)

Figure 16. Global Leuprorelin Drugs Sales (2019-2030) & (K Units)

Figure 17. Global Leuprorelin Drugs Average Price (US$/Unit) & (2019-2030)

Figure 18. Leuprorelin Drugs Report Years Considered

Figure 19. Leuprorelin Drugs Sales Share by Manufacturers in 2023

Figure 20. Global Leuprorelin Drugs Revenue Share by Manufacturers in 2023

Figure 21. Global 5 and 10 Largest Leuprorelin Drugs Players: Market Share by Revenue in Leuprorelin Drugs in 2023

Figure 22. Leuprorelin Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 23. Global Leuprorelin Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 24. North America Leuprorelin Drugs Sales Market Share by Country (2019-2030)

Figure 25. North America Leuprorelin Drugs Revenue Market Share by Country (2019-2030)

Figure 26. United States Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Canada Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Europe Leuprorelin Drugs Sales Market Share by Country (2019-2030)

Figure 29. Europe Leuprorelin Drugs Revenue Market Share by Country (2019-2030)

Figure 30. Germany Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. France Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. U.K. Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Italy Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Russia Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Leuprorelin Drugs Sales Market Share by Region (2019-2030)

Figure 36. Asia Pacific Leuprorelin Drugs Revenue Market Share by Region (2019-2030)

Figure 37. China Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Japan Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. South Korea Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. India Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Australia Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. China Taiwan Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America Leuprorelin Drugs Sales Market Share by Country (2019-2030)

Figure 45. Mexico Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Brazil Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Argentina Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Colombia Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East and Africa Leuprorelin Drugs Sales Market Share by Country (2019-2030)

Figure 50. Middle East and Africa Leuprorelin Drugs Revenue Market Share by Country (2019-2030)

Figure 51. Turkey Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. UAE Leuprorelin Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of Leuprorelin Drugs by Type (2019-2030)

Figure 55. Global Revenue Market Share of Leuprorelin Drugs by Type (2019-2030)

Figure 56. Global Leuprorelin Drugs Price (US$/Unit) by Type (2019-2030)

Figure 57. Global Sales Market Share of Leuprorelin Drugs by Application (2019-2030)

Figure 58. Global Revenue Market Share of Leuprorelin Drugs by Application (2019-2030)

Figure 59. Global Leuprorelin Drugs Price (US$/Unit) by Application (2019-2030)

Figure 60. Leuprorelin Drugs Value Chain

Figure 61. Leuprorelin Drugs Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions